Revolution Medicines (RVMD) announced that it has commenced an underwritten public offering to sell up to $600M of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities are acting as joint book-running managers for the proposed offering. UBS Investment Bank is acting as lead manager.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $80 from $70 at Stifel
- Revolution Medicines provides updates from RAS(ON) inhibitor combo studies
- Revolution Medicines provides updates from RAS(ON) inhibitor portfolio
- Erasca initiated with a Buy at Jefferies
- Revolution Medicines price target raised to $70 from $57 at Piper Sandler